Skip to content
Head to head

Trevi Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: TRVI · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

TRVI +17.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
TRVIVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price13.35515.02
Change today-2.70%-1.08%
1-year return+25.4%+22.0%
Market cap$1.90B$130.58B
52-week range9.82 – 20.22412.27 – 568.67
Valuation
P/E (TTM)-33.3833.14
P/E percentile, own 5-yr range14th99th
P/B6.296.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.3215.32
Net profit (TTM)$-45.62M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-61.69M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership111.8%96.8%
Insider activity (12mo)38 buy / 12 sell28 buy / 22 sell
Short interest (% of float)11.8%1.9%
Analyst consensus100% buy (7)95% buy / 5% hold (21)
Analyst price target$28 (+108%)$624 (+21%)
StockVane view
StockVane Quant RatingD (66)C (68)
Company
Employees346,400
Founded20111989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.